{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/3crclcp6ljg",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1371/journal.pone.0172640",
    "https://doi.org/10.1186/s13195-024-01450-7",
    "https://doi.org/10.1096/fj.202401704R"
  ],
  "dcterms:references": [
    "# Connecting DOPAL's Anti-Oligomerization Effects with Carbidopa's Neutral Impact on Amyloid-β\n\n## 1. Background\n\nAmyloid-β (Aβ) oligomerization represents a critical step in Alzheimer's disease pathogenesis, with globular oligomers demonstrating particular neurotoxicity. DOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive aldehyde metabolite of dopamine produced by monoamine oxidase (MAO), has been shown to decrease Aβ oligomerization in human neuroblastoma cells, subsequently reducing Aβ-induced cytotoxicity. Carbidopa, a peripheral dopa-decarboxylase inhibitor used in Parkinson's disease treatment alongside L-DOPA, does not significantly affect Aβ generation, unlike other dopaminergic medications that can modulate Aβ metabolism through D2R-mediated pathways (as indicated in Abstract 2).\n\n## 2. Knowledge Gap\n\nWhile we know that DOPAL reduces Aβ oligomerization and carbidopa has minimal effects on Aβ generation, the specific molecular mechanisms explaining why a dopamine metabolite (DOPAL) would inhibit Aβ oligomerization while carbidopa remains neutral remain unknown. This gap is particularly significant given the paradoxical finding in Abstract 2 that L-DOPA (dopamine's precursor) actually enhances Aβ generation through D2R/β-arrestin signaling.\n\n## 3. Central Hypothesis\n\nDOPAL prevents Aβ oligomerization through direct protein modification via aldehyde-lysine adduct formation with Aβ monomers, while carbidopa's inability to affect central nervous system DOPAL production explains its neutral effect on Aβ pathology.\n\n## 4. Proposed Mechanism\n\n1. Dopamine is metabolized by MAO to produce DOPAL, a highly reactive aldehyde that can form covalent adducts with proteins through Schiff base formation with lysine residues.\n\n2. DOPAL forms adducts with specific lysine residues on Aβ monomers (particularly Lys16 and Lys28), which are essential for the β-sheet formation necessary for oligomerization.\n\n3. These DOPAL-modified Aβ monomers cannot engage in the proper intermolecular interactions required for oligomer assembly, effectively acting as \"oligomerization terminators\" that disrupt the seeding and growth of toxic Aβ assemblies.\n\n4. Carbidopa, by inhibiting only peripheral dopa-decarboxylase without crossing the blood-brain barrier, does not alter brain dopamine metabolism to DOPAL, thus having minimal impact on the DOPAL-mediated inhibition of Aβ oligomerization.\n\n5. This mechanism is independent of the D2R/β-arrestin 2-mediated pathway through which L-DOPA and other dopaminergic medications increase Aβ generation (described in Abstract 2), explaining the opposing effects of dopamine precursors versus metabolites on Aβ pathology.\n\n## 5. Testable Predictions\n\n1. DOPAL-modified Aβ peptides should be detectable using mass spectrometry in neuroblastoma cells treated with DOPAL, with modifications primarily at Lys16 and Lys28 residues.\n\n2. Mutation of lysine residues in Aβ (Lys16Ala, Lys28Ala) should render Aβ resistant to DOPAL's anti-oligomerization effects, while not affecting oligomerization itself.\n\n3. Increasing brain DOPAL levels through selective inhibition of aldehyde dehydrogenase (which metabolizes DOPAL to DOPAC) should reduce Aβ oligomer formation in mouse models of Alzheimer's disease without affecting total Aβ production.\n\n## 6. Potential Experimental Approaches\n\n1. **In vitro biochemical analysis**: Synthesize Aβ peptides and expose them to physiologically relevant DOPAL concentrations, then use mass spectrometry to identify adduct formation sites and thioflavin-T fluorescence assays to monitor oligomerization kinetics. Compare wild-type and lysine-mutant Aβ peptides to determine site-specificity of the interaction.\n\n2. **Animal model studies**: Administer selective ALDH inhibitors (to increase brain DOPAL levels) to 5xFAD mice and measure Aβ oligomer levels using conformation-specific antibodies. Simultaneously quantify levels of DOPAL-Aβ adducts and assess cognitive function to determine if increased DOPAL correlates with reduced oligomer burden and improved cognition, independent of total Aβ levels.\n\nThis hypothesis provides a novel mechanistic framework explaining the differential effects of dopamine metabolites versus precursors on Aβ pathology, with implications for developing new therapeutic strategies targeting specific aspects of dopamine metabolism to mitigate Alzheimer's disease pathogenesis."
  ],
  "dcterms:subject": [
    "Amyloid-β",
    "globular oligomer"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Carbidopa showed little to no effect on amyloid-β generation in neuronal cells when tested alongside other anti-Parkinson's medications."
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "Although levodopa is the first-line medication for the treatment of Parkinson's disease (PD) showing unsurpassable efficiency, its chronic use causes dyskinesia. Accordingly, dopamine agonists are increasingly employed as monotherapy or in combination with levodopa to reduce the risk of motor complications. It is well recognized that patients with PD often exhibit cognitive deficits. However, clinical and animal studies assessing the effects of dopaminergic medications on cognition are controversial. Amyloid-β (Aβ) is one of the major hallmarks of Alzheimer's disease (AD), leading to progressive memory loss and cognitive deficit. Interestingly, the abnormal accumulation of Aβ is also detected in PD patients with cognitive deficits. Evidence indicated that levodopa induced a mild increase of Aβ plaque number and size in the brain of AD mouse. However, the underlying mechanism is unclear. Here we present that both levodopa and piribedil enhance the generation of Aβ and the activity of γ-secretase in human neuronal cells and primary neurons isolated from AD mouse. This effect was reduced by either the antagonism or the knockdown of dopamine D2 receptor (D2R). We further showed that in the cells expressing β-arrestin 2-biased D2R mutant, piribedil promoted cellular Aβ production to the extent comparable to the wild-type D2R whereas this activity was absent in those with G protein-biased D2R mutant. Moreover, the knockdown of β-arrestin 2 attenuated the increases of Aβ generation and γ-secretase activity mediated by levodopa or piribedil. Thus, our study suggests that targeting D2R-mediated β-arrestin function may have potential risk in the modulation of Aβ pathology.",
    "This study investigates the impact of amyloid and tau positivity on brain atrophy in cognitively normal individuals, highlighting the critical role of these biomarkers in predicting cognitive decline and disease progression in the context of Alzheimer's disease.",
    "Disease‐specific oligomers Tau assay system is anticipated in Alzheimer disease (AD) to elucidate their etiological roles. We developed a highly sensitive and selective ELISA for high‐molecular‐weight oligomer tau (HMWoTau) with LLOQ of 0.3 pg/well for the first time, using a novel mouse monoclonal antibody APNmAb005. HMWoTau species were visualized as globular particles by advanced microscopy techniques and showed significant increases in AD brains at advanced Braak stages, suggesting their potential as biomarkers for diagnosis."
  ]
}